Boothbay Fund Management’s AstraZeneca AZN Stock Holding History

Boothbay Fund Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-15,900	Closed	-$2.48M	–	1620
2024 Q2	$2.48M	Sell	15,900 -29,050	-65%	-$4.37M	0.06%	434
2024 Q1	$6.09M	Buy	+44,950	New	+$5.95M	0.12%	175
2023 Q3	–	Sell	-172,650	Closed	-$24.7M	–	1727
2023 Q2	$24.7M	Buy	172,650 +119,150	+223%	+$17.5M	0.54%	18
2023 Q1	$7.43M	Buy	+53,500	New	+$7.2M	0.15%	134
2021 Q4	–	Sell	-5,050	Closed	-$607K	–	1862
2021 Q3	$607K	Buy	+5,050	New	+$588K	0.02%	999
2021 Q2	–	Sell	-182	Closed	-$1.81M	–	1840
2021 Q1	$1.81M	Hold	182	–	–	0.07%	355
2020 Q4	$1.82M	Buy	+182	New	+$19.3K	0.07%	292

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Boothbay Fund Management's AZN Position: Q2 2026 in Review

Boothbay Fund Management increased its AstraZeneca (AZN) stake by 1.1% in Q2 2026, buying an estimated $7.9K and bringing the position to 3,909 shares worth $741K. The position accounts for 0.01% of the portfolio, ranked #1276.

Boothbay Fund Management first reported a position in AZN in Q3 2019 and has held it in 18 quarters since. The position peaked at $10.2M in Q1 2021. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Boothbay Fund Management held 3,909 shares of AstraZeneca worth $741K as of Q2 2026.
Boothbay Fund Management bought 42 AstraZeneca shares in Q2 2026, an estimated $7.9K.
AstraZeneca made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1276 holding.
Boothbay Fund Management first reported a position in AstraZeneca in Q3 2019 and has held it in 18 quarters since.
Boothbay Fund Management's AstraZeneca position peaked at $10.2M in Q1 2021.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.